Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBriefing
STAT says biotech M&A is “off the charts,” yet French drugmaker Abivax remains independent. The gap itself…
The WeekDrug Channels ↗
Today's guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx. Geoffrey and Matth…
The WeekPharmaceutical Technology ↗
Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical for a…
The WeekSTAT News ↗
AI products from Cadence and Limbic are among four devices recently accepted into the FDA's TEMPO pilot that w…
The WeekBioPharma Dive ↗
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect …
The WeekPharmaVoice ↗
Gilead's new "Up to Date" campaign uses humor and dating scenarios to reach Black communities amid persistent …
The WeekFiercePharma ↗
After pivoting from mobile gaming marketing to pharma, Genentech performance marketing engagement lead Tiffany…
The WeekFierceBiotech ↗
The overwhelming demand for GLP-1 weight loss drugs has reshaped the drug market, empowering consumers to take…
The WeekBriefing
A FiercePharma podcast summary points to a fireside chat with Ira Mellman and Axel Hoos at the 2026 Immuno-Onc…
The WeekPharmaceutical Technology ↗
Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discover…
The WeekSTAT News ↗
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in r…
The WeekBioPharma Dive ↗
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren't…
The WeekPharmaVoice ↗
CAR-T's commercial challenge isn't making bigger batches. It's making thousands of patient-specific manufactur…
The WeekFiercePharma ↗
Emergent BioSolutions looks to expand awareness and education of its Narcan opioid overdose reversal spray wit…
The WeekFierceBiotech ↗
GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a …
The WeekBriefing
Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion. The strategic read is a platform move int…
The WeekPharmaceutical Technology ↗
The US FDA has approved PharmaEssentia's Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential…
The WeekSTAT News ↗
An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, th…
The WeekFiercePharma ↗
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the indust…
The WeekFierceBiotech ↗
Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, jus…
The WeekBriefing
Lilly’s latest 2026 acquisition targets protein degradation in autoimmune disease. The limited details still s…
The WeekBioPharma Dive ↗
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and …
The WeekPharmaceutical Technology ↗
Several treatment guidelines worldwide recommend the use of SGLT2 inhibitors as a treatment for all types of h…
The WeekSTAT News ↗
"There has been a wealth of new treatment available" for migraine prevention, said a co-author of new guidelin…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.